Concepedia

Marco Campioni

MC

Statistics

Publications

8

Citations

188

H-Index

8

Active since

2016

Affiliations

Amgen (Switzerland)(Current)

Amgen (United States)

National and Kapodistrian University of Athens

University of Chicago

Amgen (United Kingdom)

Marco Campioni is an author at Amgen (Switzerland) specializing in multiple myeloma, multiple myeloma therapy, and multiple myeloma treatment.

Publications per year

2016–2019

8

Publications

8

Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective

Andrzej Jakubowiak, Marco Campioni, Ágnes Benedict et al. · Journal of Medical Economics · 2016 · 51 citations · Full text

, , +17

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States

Thomas E. Delea, Xinke Zhang, Jordan Amdahl et al. · PharmacoEconomics · 2019 · 26 citations · Full text

, , +17

Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies

Roman Hájek, Jiří Jarkovský, Vladimír Maisnar et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 24 citations

, , +14

Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States

Andrzej Jakubowiak, Ivan Houisse, István Májer et al. · Expert Review of Hematology · 2017 · 23 citations

, , +17

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy

Evangelos Terpos, Aurélien Jamotte, A Christodoulopoulou et al. · Journal of Medical Economics · 2019 · 20 citations · Full text

, , +17

1–5 of 8